Alkermes logo

ALKS - Alkermes Share Price

$22.87 0.7  3.1%

Last Trade - 25/01/21

Sector
Healthcare
Size
Large Cap
Market Cap £2.58bn
Enterprise Value £2.37bn
Revenue £856.1m
Position in Universe 1639th / 6623
Bullish
Bearish
Unlock ALKS Revenue
Momentum
Relative Strength (%)
1m +0.31%
3m
6m
1yr
Volume Change (%)
10d / 3m
Price vs... (%)
52w High -3.61%
50d MA
200d MA
Growth & Value
12m Forecast Rolling Industry Market
Valuation (ttm) Industry Market
Margin of Safety
Qualifying GuruScreens
Financial Summary
Year End 31st Dec 2014 2015 2016 2017 2018 2019 2020E 2021E CAGR / Avg
618.8 628.3 745.7 903.4 1,094 1,171 1,026 1,120 +13.6%
+34.5
PEG
Profitability
ROA
%
%
Cashflow
Dividends
Balance Sheet
NFA
m
FINANCIAL BRIEF: : For the nine months ended 30 September 2020,Alkermes Plc revenues increased less than 1% to $758.8M.Net loss decreased 64% to $68.2M., also reflectRoyalty-INVEGA SUSTENNA/XEPLION & INVEGA TRINZA/TREVICTAsegment decrease of 63% to $69.4M, VIVITROL segmentdecrease of 37% to $151.9M. Lower net loss reflectsIncrease in the fair value of contingent increase from$27.8M (expense) to $16.6M (income), Selling.
Health Trend(F-Score)
0 1 2 3 4 5 6 7 8 9
Bankruptcy Score(Z-Score)
Distress
Cautious
Safe
Earnings Manipulation Risk(M-Score)
Other Ratios
Recent History
Latest interim period vs. prior period Industry Market
3yr Compound Annual Growth Rate Industry Market
Graphical History

Revenue

ALKS Revenue Unlock ALKS Revenue

Net Income

ALKS Net Income Unlock ALKS Revenue

Normalised EPS

ALKS Normalised EPS Unlock ALKS Revenue

PE Ratio Range

ALKS PE Ratio Range Unlock ALKS Revenue

Dividend Yield Range

ALKS Dividend Yield Range Unlock ALKS Revenue
Analyst Forecasts
Price Target:
( below Price)
31st Dec 2021
31st Dec 2022
Est. Long Term Growth Rate: Net Profit
()
EPS
()
DPS
()
Net Profit
()
EPS
()
DPS
()
Consensus Estimate
1m Change
3m Change
Analyst Consensus
Strong Sell Sell Hold Buy Strong Buy
EPS 2019 /  2020
ALKS EPS Forecasts Unlock ALKS Revenue
Profile Summary

Alkermes plc is a biopharmaceutical company. The Company is engaged in the researching, developing and commercializing pharmaceutical products that are designed to address medical needs of patients in therapeutic areas. The Company has a portfolio of marketed drug products and a clinical pipeline of products that address central nervous system (CNS) disorders, such as schizophrenia, depression, addiction and multiple sclerosis (MS). The Company's products include ARISTADA, VIVITROL, INVEGA SUSTENNA, XEPLION, INVEGA TRINZA, TREVICTA, RISPERDAL CONSTA, AMPYRA, FAMPYRA, BYDUREON, Aripiprazole lauroxil, ALKS 5461, ALKS 3831, ALKS 8700, ALKS 6428, ALKS 4230 and ALKS 7119. The Company's product platforms include injectable extended-release microsphere technology, LinkeRx technology, NanoCrystal technology and oral controlled release (OCR) technology. ARISTADA is an extended-release intramuscular injectable suspension for the treatment of schizophrenia.

Directors
Last Annual December 31st, 2019
Last Interim September 30th, 2020
Incorporated May 4, 2011
Public Since July 16, 1991
No. of Shareholders: 112
No. of Employees: 2,235
Sector Healthcare
Industry Biotechnology & Medical Research
Index Nasdaq Composite ,
Exchange NASDAQ Global Select Market
Shares in Issue 159,149,785
Free Float (0.0%)
Eligible for
ISAs
SIPPs
ALKS Share Price Performance
Share Price
Bid - Ask
Low - High
Spread
Day's Change
Avg Volume
Open - Close
Range (12m)
Beta
Latest News for ALKS
Upcoming Events for ALKS
Wednesday 10th February, 2021 Estimate
Q4 2020 Alkermes Plc Earnings Release
Tuesday 27th April, 2021 Estimate
Q1 2021 Alkermes Plc Earnings Release
Frequently Asked Questions for Alkermes
What is the Alkermes share price?

As of 25/01/21, shares in Alkermes are trading at $22.87, giving the company a market capitalisation of £2.58bn. This share price information is delayed by 15 minutes.

How has the Alkermes share price performed this year?

Shares in Alkermes are currently trading at $22.87 and the price has moved by 21.92% over the past 365 days. In terms of relative price strength - which takes into account the overall market trend - the Alkermes price has moved by 4.28% over the past year.

What are the analyst and broker recommendations for Alkermes?

Of the analysts with advisory recommendations for Alkermes, there are there are currently 0 "buy" , 10 "hold" and 0 "sell" recommendations. The overall consensus recommendation for Alkermes is Hold. You can view the full broker recommendation list by unlocking its StockReport.

When will Alkermes next release its financial results?

Alkermes is scheduled to issue upcoming financial results on the following dates:

Interim results are scheduled for: 2021-09-30
What is the Alkermes dividend yield?

Alkermes does not currently pay a dividend.

Does Alkermes pay a dividend?

Alkermes does not currently pay a dividend.

When does Alkermes next pay dividends?

Alkermes does not currently pay a dividend.

How do I buy Alkermes shares?

To buy shares in Alkermes you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.

What is the market cap of Alkermes?

Shares in Alkermes are currently trading at $22.87, giving the company a market capitalisation of £2.58bn.

Where are Alkermes shares listed? Where are Alkermes shares listed?

Here are the trading details for Alkermes:

Country of listing: United States
Exchange: NSQ
Ticker Symbol: ALKS
What kind of share is Alkermes?

Based on an overall assessment of its quality, value and momentum, Alkermes is currently classified as a High Flyer. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.

Is there a Alkermes share price forecast 2021?

Shares in Alkermes are currently priced at $22.87. At that level they are trading at 3.74% premium to the analyst consensus target price of 0.00.

Analysts covering Alkermes currently have a consensus Earnings Per Share (EPS) forecast of 0.394 for the next financial year.

How can I tell whether the Alkermes share price will go up?

An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Alkermes. Over the past six months, the relative strength of its shares against the market has been -5.73%. At the current price of $22.87, shares in Alkermes are trading at 23.98% against their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.

What is the Alkermes PE Ratio?

We were not able to find PE ratio data for Alkermes.

Who are the key directors of Alkermes?

Alkermes's management team is headed by:

David Anstice - LED
Robert Breyer - IND
Wendy Dixon - IND
Richard Pops - CHM
Shane Cooke - DRC
Michael Landine - SVP
Iain Brown - CFO
Craig Hopkinson - EVP
David Gaffin - SVP
David Daglio - IND
Blair Jackson - COO
Who are the major shareholders of Alkermes?

Here are the top five shareholders of Alkermes based on the size of their shareholding:

T. Rowe Price Associates, Inc. Investment Advisor
Percentage owned: 14.73% (23.4m shares)
Wellington Management Company, LLP Investment Advisor/Hedge Fund
Percentage owned: 13.79% (21.9m shares)
The Vanguard Group, Inc. Investment Advisor/Hedge Fund
Percentage owned: 9.47% (15.1m shares)
Vanguard Health Care Fund Mutual Fund
Percentage owned: 8.55% (13.6m shares)
Sarissa Capital Management, L.P. Hedge Fund
Percentage owned: 4.92% (7.83m shares)
Similar to ALKS
© Stockopedia 2021, Refinitiv, Share Data Services.
This site cannot substitute for professional investment advice or independent factual verification. To use it, you must accept our Terms of Use, Privacy and Disclaimer policies.